Journal Home > Volume 5 , Issue 1
Objective:

To observe the result of olfactory ensheathing cell (OEC) transplantation in a patient with chronic sciatic nerve injury.

Case report:

A 53-year-old male patient with chronic (1 year) sciatic nerve injury on left side received OEC transplantation at the lesion site. He received follow-up assessment according to the American Spinal Injury Association standard at 10 days, 6 months, and 1 year after OEC therapy. The muscle strength of his left lower limb increased and numbness decreased during the early stage of cell therapy. His motor function improved with each evaluation. His limp walking gait recovered, and numbness sensation got nearly normal after 1 year of follow-up. There were no side effects.

Conclusion:

OEC transplantation may be an option for chronic peripheral (sciatic) nerve injury.


menu
Abstract
Full text
Outline
About this article

Olfactory ensheathing cell transplantation for a patient with chronic sciatic nerve injury

Show Author's information Feng Zhang1,2Xiangzhi Meng2Fang Lu2Aixian Liu2Hongyun Huang1,2( )
Cell Therapy Center, Beijing Hongtianji Neuroscience Academy,
Neurorehabilitation Center, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, People’s Republic of China

Abstract

Objective:

To observe the result of olfactory ensheathing cell (OEC) transplantation in a patient with chronic sciatic nerve injury.

Case report:

A 53-year-old male patient with chronic (1 year) sciatic nerve injury on left side received OEC transplantation at the lesion site. He received follow-up assessment according to the American Spinal Injury Association standard at 10 days, 6 months, and 1 year after OEC therapy. The muscle strength of his left lower limb increased and numbness decreased during the early stage of cell therapy. His motor function improved with each evaluation. His limp walking gait recovered, and numbness sensation got nearly normal after 1 year of follow-up. There were no side effects.

Conclusion:

OEC transplantation may be an option for chronic peripheral (sciatic) nerve injury.

Keywords: neurorestoration, olfactory ensheathing cell transplantation, peripheral nerve injury, sciatic nerve injury, function improvement

References(29)

1.
Radtke C, Kocsis J. Peripheral nerve injuries and transplantation of olfactory ensheathing cells for axonal regeneration and remyelination: fact or fiction? Int J Mol Sci. 2012;13:12911−12924.
2.
Deumens R, Koopmans G, Lemmens M, et al. Neurite outgrowth promoting effects of enriched and mixed OEC/ONF cultures. Neurosci Lett. 2006;397(1-2):20-24.
3.
Au E, Richter M, Vincent A, et al. SPARC from olfactory ensheathing cells stimulates Schwann cells to promote neurite outgrowth and enhances spinal cord repair. J Neurosci. 2007;29:7208-7236.
4.
Cao L, Zhu Y, Su Z, et al. Olfactory ensheathing cells promote migration of Schwann cells by secreted nerve growth factor. Glia. 2007;55:897-904.
5.
Verdú E, Navarro X, Gudiño-Cabrera G, et al. Olfactory bulb ensheathing cells enhance peripheral nerve regeneration. Neuroreport. 1999;10:1097-1101.
6.
Dombrowski M, Sasaki M, Lankford K, Kocsis J, Radtke C. Myelination and nodal formation of regenerated peripheral nerve fibers following transplantation of acutely prepared olfactory ensheathing cells. Brain Res. 2006;1127:1-8.
7.
Cheng S, Ruan H, Wu X. [Olfactory ensheathing cells enhance functional recovery of injured sciatic nerve]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2003;17:18-36. Chinese.
8.
Delaviz H, Joghataie M, Mehdizadeh M, Bakhtiyari M, Nobakht M, Khoei S. Transplantation of olfactory mucosa improve functional recovery and axonal regeneration following sciatic nerve repair in rats. Iran Biomed J. 2008;12:197-202.
9.
Radtke C, Aizer A, Agulian S, Lankford K, Vogt P, Kocsis J. Transplantation of olfactory ensheathing cells enhances peripheral nerve regeneration after microsurgical nerve repair. Brain Res. 2009;1274:10-17.
10.
People’s Republic of China, Ministry of Public Health, Science and Technology Bureau, 1991. Instruction for prepare and clinical application of the aborted human fetuses (91-006).
DOI
11.
Chen L, Xi H, Huang H, et al. Multiple cell transplantation based on an intraparenchymal approach for patients with chronic phase stroke. Cell Transplant. 2013;22 (Suppl 1):S83-S91.
12.
Xi H, Chen L, Huang H, et al. Preliminary report of multiple cell therapy for patients with multiple system atrophy. Cell Transplant. 2013;22 (Suppl 1):S93-S99.
13.
Huang H, Raisman G, Sanberg PR, Sharma H, Chen L. Neurorestoratology, V4. New York: Nova Biomedical; 2015:313-357.
DOI
14.
Jin W-H, Wei Z-R, Sun G-F, Tang X-J, Wang D-L. Autologous peripheral blood stem cell transplantation for treatment of peripheral nerve injury. Available from: http://www.crter.org/CN/abstract/abstract176.shtml. Accessed August 24, 2016.
DOI
15.
Rodrigues MC, Rodrigues AA, Glover LE Jr, Voltarelli J, Borlongan CV. Peripheral nerve repair with cultured Schwann cells: getting closer to the clinics. Sci World J. 2012;(5):413091.
16.
Millesi H. Factors affecting the outcome of peripheral nerve surgery. Microsurgery. 2006;26(4):295−302.
17.
Huang H, Chen L, Sanberg P. Cell therapy from bench to bedside translation in CNS neurorestoratology era. Cell Med. 2010;1(1):15−46.
18.
Huang H, Raisman G, Sanberg PR, Sharma H, Chen L. Neurorestoratology, V1. New York: Nova Biomedical; 2015:67-91.
DOI
19.
Huang HY, Chen L, Wang HM, et al. Influence of patients’ age on functional recovery after transplantation of olfactory ensheathing cells into injured spinal cord injury. Chin Med J. 2003;116(10):1488−1491.
20.
Huang H, Chen L, Xi H, et al. Fetal olfactory ensheathing cells transplantation in amyotrophic lateral sclerosis patients: a controlled pilot study. Clinical Transplant. 2008;22:710-718.
21.
Chen L, Huang H, Xi H, et al. Intracranial transplant of olfactory ensheathing cells in children and adolescents with cerebral palsy: a randomized controlled clinical trial. Cell Transplant. 2010;19(2):185−191.
22.
Huang H, Chen L, Xi H, et al. [Olfactory ensheathing cells transplantation for central nervous system diseases in 1,255 patients]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2009;23(1):14−20. Chinese.
23.
Chen L, Huang H, Xi H, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries. Cell Transplant. 2014;23 (Suppl 1):S35-S44.
24.
Chen L, Chen D, Xi H, et al. Olfactory ensheathing cell neurorestorotherapy for amyotrophic lateral sclerosis patients: benefits from multiple transplantations. Cell Transplant. 2012;21 (Suppl 1):S65-S77.
25.
Huang H, Xi H, Chen L, Zhang F, Liu Y. Long-term outcome of olfactory ensheathing cell therapy for patients with complete chronic spinal cord injury. Cell Transplant. 2012;21 (Suppl 1):S23-S31.
26.
Guérout N, Duclos C, Drouot L, et al. Transplantation of olfactory ensheathing cells promotes axonal regeneration and functional recovery of peripheral nerve lesion in rats. Muscle Nerve. 2011;43(4):543−551.
27.
You H, Wei L, Liu Y, et al. Olfactory ensheathing cells enhance Schwann cell-mediated anatomical and functional repair after sciatic nerve injury in adult rats. Exp Neurol. 2011;229(1):158−167.
28.
Huang H, Wang H, Chen L, et al. [Influence factors for functional improvement after Olfactory ensheathing cell transplantation for chronic spinal cord injury]. Zhongguo Xiufu Chongjian Waike Zazhi. 2006;20(4):434−438.
29.
Steinberg GK, Kondziolka D, Wechsler LR, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a Phase 1/2a study. Stroke. 2016;47(7):1817−1824.
Publication history
Copyright
Rights and permissions

Publication history

Published: 28 December 2017
Issue date: December 2017

Copyright

© 2017 The Author(s).

Rights and permissions

© 2017 Zhang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

Return